The “Battle of the Pills” continues in HIV, breast cancer, UC/Crohn’s and HS. Listen as Kerry and Luisa consolidate their thoughts after the latest Q4 results calls on the upcoming clinical trial readouts for long-acting HIV medicines (GSK, Gilead), oral SERDs in breast cancer (AstraZeneca, Eli Lilly, Roche), TL1A’s in UC/Crohn’s (AbbVie, Merck & Co, Roche, Sanofi/Teva) and HS (AbbVie, Novartis, UCB).